Abstract

Coronary artery disease evolution in bare-metal stent implantation: safety and efficacy of REBEL platinum “chromium coronary stent system

Author(s): P Gatto & D Carrie

Coronary artery disease affects over 5,000,000 people worldwide. Despite technology evolution and extension of indications of drug-eluting and bioresorbable stents, bare-metal stents play an important role to treat single lesions less than 15 mm of length and/or greater than 2.5 mm of diameter. The REBEL™ stent is made from a new platinum–chromium alloy combined with a customized stent architecture and an enhanced delivery system that allows improved performances of this stent such as high radial and axial strength and lower stent recoil. The feasibility and efficacy of percutaneous implantation has been studied worldwide with a prospective, single-arm, multicenter, clinical trial with a de novo atherosclerotic coronary artery lesion currently underway.